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1. INTRODUCTION 
The peptidic vasopressor hormones, vasopressin 
and angiotensin II, share the ability to stimulate 
hepatic glycogenolysis and gluconeogenesis [ l-41. 
These effects of the hormones are absolutely de- 
pendent on the presence of extracellular calcium 
[l-4]. It is generally accepted that both hormones 
have similar mechanisms of signal transduction 
which are cyclic AMP-independent and involve 
modulation of the cellular calcium fluxes [l-6]. 
Phosphatidylinositol turnover is associated with 
their effects and it might play a role in the process of 
signal transduction (reviewed in (71). 
min (fraction V) and collagenase (type II) were ob- 
tained from Armour and Worthington, respective- 
ly. Glucagon was a generous gift from Eli Lilly. 
[2,8-3H]Adenosine 3’,5’-cyclic phosphate was ob- 
tained from New England Nuclear. 
Angiotensin II (but not vasopressin) inhibited 
adenylate cyclase in a purified preparation of liver 
plasma membrane [8]. The data suggest two recep- 
tors for angiotensin II in liver cells with different 
mechanisms of signal transduction: one of the re- 
ceptors acting through a calcium-signalling process; 
the other through inhibition of adenylate cyclase. 
The effect of angiotensin II and vasopressin on 
the actions of glucagon on cyclic AMP levels, gly- 
cogenolysis, gluconeogenesis and ureogenesis were 
investigated in hepatocytes incubated in cal- 
cium-free buffer. 
2. MATERIALS AND METHODS 
Angiotensin II, arginine-vasopressin, D,L-lactate 
(sodium salt), L-glutamine, L-ornithine, glycerol, 
glucose oxidase, peroxidase and urease were obtain- 
ed from Sigma Chemical Co. Bovine serum albu- 
Hepatocytes were isolated from female Wistar 
rats as in [9]. The cells were washed and incubated 
in Krebs-Ringer bicarbonate buffer (without 
CaCl2) containing 1% albumin and 0.5 mM EGTA 
(pH 7.4) under an atmosphere of 02-CO2 (95:5, 
v/v). Incubations were for 60 min at 37°C in 1 ml 
Krebs-Ringer bicarbonate buffer. Glucose produc- 
tion (in the absence of exogenous substrates) by 
hepatocytes from fed rats was considered as an in- 
dex of glycogenolysis. Synthesis of glucose in the 
presence of 10 mM L-lactate by hepatocytes from 
24 h fasted rats was considered as gluconeogenesis 
(glucose production in the absence of substrate re- 
presented lo-15% of the total and it was subtract- 
ed). Glucose was determined enzymatically [lo]. 
Urea production was determined in cells from fed 
rats in medium supplemented with 2 mM ornithine 
and 10 mM glutamine and was determined as in 
[ 111. Cyclic AMP accumulation was measured in 
cells from fed animals incubated in medium con- 
taining 100 PM theophylline, 2 min after the addi- 
tion of the agents to be tested, as in [ 121. Statistical 
significance of the difference between comparable 
groups was determined by Student’s t-test. 
3. RESULTS 
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resulted in a basal level of cyclic AMP of 0.36 + 0.02 I 
pmol/mg cells wet wt (mean k SEM, n = 37). 
u) = 
Vasopressin (10 mu/ml) and angiotensin II (10 ~ 6 - 6 : CT 
M) were without significant effect on this basal 
value. Glucagon increased the level of the cyclic 
nucleotide in a dose-dependent manner reaching a 
E 
‘4 
> 
E 
a 
maximum at 10 - ’ M (4.98 + 0.33 pmol/mg cells 
wet wt; mean 2 SEM, n = 39). Vasopressin (up to 
10 mu/ml) was without effect on this glucagon- 
induced cyclic AMP accumulation (glucagon 10 - 7 
3 
0 
72 
M + vasopressin 10 mU/ml, 4.87 2 0.40 pmol/ 
mg cells wet wt; mean t SEM, n = 16). How- 
---.‘I 
: L 
ever, angiotensin II produced a dose-dependent 
9 6 7 6 5 
diminution of the cyclic AMP levels due to 10 - 7 -LOG [ANGIOTENSIN Ir] M 
M glucagon (fig.1). The maximal diminution 
(- 50%) was obtained at 10 -6 M angiotensin II Fig. 1. Dose-response curve for the effect of angiotensin 
(2.30 + 0.23 pmol/mg cells wet wt, mean 4 SEM, 
II on the accumulation of cyclic AMP due to 10 ~ ’ M 
n = 39; p < 0.001 compared to glucagon alone). 
glucagon. Hepatocytes were incubated for 2 min in buffer 
The effect of the maximally effective concentra- 
containing 100 PM theophylline, 10 ~ ’ M glucagon and 
tion of angiotensin II (10 - 6 M) on the dose- 
different concentrations of angiotensin II. Results are the 
means and vertical lines represent the SEM of 30-40 
response curves to glucagon for glycogenolysis, determinations. 
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Fig.2. Dose-response curves for the effects of glucagon on glycogenolysis, gluconeogenesis and ureogenesis in the 
absence or presence of 10W6 M angiotensin II. Hepatocytes were incubated for 60 min with different concentrations of 
glucagon in the absence or presence of 10 - 6 M angiotensin II. Basal glycogenolysis was 21 ‘_ 3 nmol/mg cells wet wt, 
basal gluconeogenesis 4.5 + 0.2 nmol/mg cells wet wt and basal ureogenesis was 16.5 2 1.5 nmol/mg cells wet wt. Results 
are the means and vertical lines represent the SEM of 4-8 cell prep. 
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gluconeogenesis and ureogenesis was studied. The 
dose-response curves in the absence or presence 
of angiotensin II were not significantly different 
(lig.2). Angiotensin II alone was without effect on 
these parameters (glycogenolysis 106 2 3; gluco- 
neogenesis 107 + 5 and ureogenesis 107 + 3; 
results are expressed as % of control value and are 
the means f SEM of 4-8 cell preps). 
4. DISCUSSION 
These results confirm in whole hepatocytes the 
reported inhibition of adenylate cyclase by angio- 
tensin II in liver plasma membranes [S], which sug- 
gests that the effect of the pressor hormone occurs 
in the membrane of parenchymal cells. In addition 
the effect of angiotensin II in whole cells is observed 
in calcium-free medium in contrast to its effects on 
glycogenolysis and gluconeogenesis [l-4]. Vaso- 
pressin did not share this ability to inhibit adenylate 
cyclase ([8], this work). Phosphatidylinositol label- 
ling is another calcium-independent effect of an- 
giotensin II. However, this effect and the cal- 
cium-dependent metabolic effects (stimulation of 
glycogenolysis and gluconeogenesis) are also pro- 
duced by vasopressin. Our data support the sugges- 
tion [8] that two types of receptors for angiotensin 
II coupled to different mechanisms of signal trans- 
duction may exist in the liver cell. The possibility 
that a single type of receptor for angiotensin II (in 
contrast to the vasopressin receptor) might be 
coupled to both systems of signal transduction can- 
not be ruled out. However, a large amount of evidence 
suggests that some receptor subtypes are coupled to 
different systems of signal transduction (reviewed 
in [ 13,141). The pharmacological characterization of 
receptor subtypes cannot be properly performed 
until selective agonists and antagonists become 
available. 
The inhibition of adenylate cyclase by angio- 
tensin II, as reflected by the decreased accumulation 
of cyclic AMP, was only observed when the cyclase 
was stimulated by glucagon. Monovalent cations 
stimulate adenylate cyclase in isolated membranes 
[8] and seem to be required to observe the inhibition 
of the cyclase by angiotensin II [8]. Both conditions 
(addition of monovalent ions in plasma membrane 
preparations and glucagon in whole cells) might 
represent better kinetic conditions, allowing obser- 
vation of the inhibition. 
It is generally accepted that the effects of gluca- 
gon are mediated through cyclic AMP: Angiotensin 
II which markedly decreases the accumulation of 
cyclic AMP due to glucagon should shift to the right 
the dose-response curves for glucagon. However, 
no shift or decrease in the maximal stimulation 
was detected. Therefore, this experiment provides a 
circumstance in which the effect of glucagon on 
cyclic AMP levels can be dissociated from its meta- 
bolic effects. Adenosine, which also inhibits aden- 
ylate cyclase, produces a similar dissociation [ 151. 
Factor(s) besides cyclic AMP could be involved in 
glucagon action ([ 161, this work). Nevertheless, a 
pool of adenylate cyclase inaccessible to the recep- 
tors for angiotensin II might be responsible for the 
effects of glucagon. 
Our results support the following suggestions: 
(i) Two receptors for angiotensin II coupled to 
different mechanisms of signal transduction 
might exist in liver cells; 
(ii) Factors besides cyclic AMP could play a role in 
the action of glucagon. 
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